EU accepts marketing application for Paratek’s antibiotic
European regulators have accepted an application from Paratek Pharmaceuticals seeking approval of the broad-spectrum antibiotic omadacycline for two types of infection.
Read More
Tag: CABP
US regulatory panel backs Cempra’s new antibiotic
Advisors to the US Food and Drug Administration have narrowly backed approval of Cempra’s new antibiotic solithromycin as a treatment for community acquired bacterial pneumonia (CABP).
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
